RNS
Reach
Diaceutics
PLC
Diaceutics Strengthens
Leadership Team with appointment of Ken Ruppel as VP of Scientific
and Medical Services
Belfast and London, 5 February - Diaceutics PLC (AIM:
DXRX), a leading technology and
solutions provider to pharma and biotech companies, is pleased to
announce the appointment of Ken Ruppel as Vice President of
Scientific & Medical Services, effective February 1st
2024.
With a commitment to ensuring every
patient has access to the right treatment at the right time,
Diaceutics welcomes Ken to lead the expansion of current offerings
and development of innovative solutions in precision
medicine.
Ken joins Diaceutics with an
impressive background of over 25 years' experience delivering
commercial and operational success in the medical research, life
sciences, pharmaceutical, biotechnology and clinical diagnostic
markets. He most recently served as VP of Precision Medicine at
Amplity Health, where he played a pivotal role in supporting the
launch of over 20 companion diagnostic indications across diverse
tumour types and laboratory methodologies in the US. His strategic
expertise was instrumental in guiding Precision Medicine strategies
and tactics for 12 pharmaceutical brands and his impressive track
record showcases his dedication to advancing precision medicine
initiatives.
In his role at Diaceutics, Ken will
lead the identification, development and support of strategic
growth opportunities within Scientific & Medical products and
services. His responsibilities will include driving innovation and
leading client interactions.
Ken's passion and expertise in
diagnostic enabled therapies will play a significant role in
realising the company's core mission - making precision medicine
globally accessible through the DXRX platform.
Susanne Munksted, Chief Precision Medicine Officer at
Diaceutics, commented:
"We are extremely pleased to welcome Ken to Diaceutics as our
VP Scientific and Medical Services. His proven track record in
Precision Medicine aligns seamlessly with our vision, and we are
confident in his ability to lead our Scientific and Medical team to
be a driving force towards success."
Enquiries:
|
Diaceutics PLC
|
|
|
Ryan Keeling, Chief Executive
Officer
|
Tel: +44 (0)28 9040
6500
|
|
Nick Roberts, Chief Financial
Officer
|
investorrelations@diaceutics.com
|
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7710
7600
|
|
Ben Maddison
|
|
|
Nick Harland
|
|
|
Kate Hanshaw
|
|
|
|
|
|
Alma Strategic Communications
|
Tel: +44(0)20 3405
0205
|
|
Caroline Forde
|
diaceutics@almastrategic.com
|
|
Kinvara Verdon
|
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome.
We provide the world's leading pharma
and biotech companies with an end-to-end commercialisation solution
for precision medicines through data analytics, scientific and
advisory services enabled by our platform DXRX - The Diagnostics
Network ®
